Tag: Rare Diease
-
The Missing Moment: When Patient Voice Enters Strategy Too Late
Patient insight often enters strategy after key decisions are already set, limiting its ability to shape evidence, positioning, and adoption. Introduced earlier, it informs the choices that drive differentiation, value…
-
How FDA Scrutiny and Patient Behavior Are Reshaping DTC’s Role in the US
DTC still drives awareness in the US, but it does not consistently support patient action on its own. FDA scrutiny and more complex patient journeys are shifting its role within…
-
RWE Reality Check: Closing the Gap Between Data and Decision-Making in Medical Affairs
Medical Affairs teams have more real-world data and more advanced analytics than ever, but decision-making is not getting easier. This article explores why more RWE and AI are not translating…
-
Medical Affairs ROI: Turning Scientific Engagement Into Measurable Impact
Interactions led by Medical Affairs, including scientific exchange with HCPs and engagement with patients and advocacy groups, can influence clinical decisions and patient behavior, but their impact is not always…
-
Cheryl Lubbert, CEO of Reverba Global, Named 2026 HBA Luminary Award Honoree
Cheryl Lubbert, CEO of Reverba Global, has been named a 2026 HBA Luminary Award honoree by the Healthcare Businesswomen’s Association. The recognition reflects her leadership in advancing scientific engagement and…
-
Perspective From Patients as Partners: Sustaining Patient Engagement Through Organizational Changes
At Patients as Partners 2026, CEO Cheryl Lubbert shared how sustaining patient engagement through organizational change requires intentional design, with systems built to hold as teams, priorities, and programs shift.
-
Pharma USA 2026: AI Scales Reach in Pharma. But What Actually Changes Patient and HCP Behavior?
AI is becoming a baseline expectation in pharma. At Pharma USA 2026, discussions reflected less focus on whether AI should be used and more on how it is being applied…
-
Approval Is Not the Finish Line: Turning Late-Stage Clinical Evidence Into Real-World Impact
Late-stage clinical programs establish the evidence required for regulatory evaluation, but they do not guarantee adoption, access, or commercial performance. Translating that evidence into real-world impact requires patient-centered execution and…
-
How Peer Mentors Help Patients Start and Stay on Therapy in Rare Disease
In rare disease, a missing piece in starting and staying on therapy is often lived perspective. Patients and their care partners may begin rare disease treatment with no peer reference…
-
Six Patient Engagement “Trends” We Should Have Outgrown by 2026
By Cheryl Lubbert, Reverba Global CEO. A New-Year Perspective on Patient Engagement The biopharma industry talks a good game about patient engagement. We talk about personalization, digital transformation, empowerment, omnichannel…
-
Elevating Voices, Empowering Futures: Mentorship as a Catalyst for Change in Biopharma
By Cheryl Lubbert, Reverba Global CEO. In biopharma, where innovation depends on both scientific discovery and human connection, mentorship stands as one of the most powerful forces for progress. It’s…
-
Bridging Science and Strategy: Medical Affairs at the Heart of Omnichannel Engagement
In this video podcast hosted by Pharmaphorum, Editor in Chief Jonah Comstock speaks with Cheryl Lubbert, co-founder and CEO of Reverba Global, and Carolyn Whiting, SVP of Clinical and Medical…